

# Stine BrÃndegaard Winther

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9324902/publications.pdf>

Version: 2024-02-01

13  
papers

288  
citations

1162889

8  
h-index

1372474

10  
g-index

13  
all docs

13  
docs citations

13  
times ranked

309  
citing authors

#	ARTICLE	IF	CITATIONS
1	Frailty screening for predicting rapid functional decline, rapid progressive disease, and shorter overall survival in older patients with gastrointestinal cancer receiving palliative chemotherapy - a prospective, clinical study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 578-584.	0.5	18
2	Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy – The Randomized NORDIC9-Study. <i>Cancers</i> , 2021, 13, 2604.	1.7	13
3	Information provision to older patients receiving palliative chemotherapy: a quality study. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-003074.	0.8	0
4	TAS-102 plus bevacizumab in metastatic colorectal cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e227.	5.1	0
5	TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 412-420.	5.1	140
6	Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 376-388.	3.7	43
7	S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 573-578.	1.1	9
8	Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. <i>BMC Cancer</i> , 2017, 17, 548.	1.1	13
9	Pre-planned safety analysis of NORDIC 9: A randomized trial comparing full dose monotherapy (S-1) with reduced dose combination therapy (S-1/oxaliplatin) in older chemo-naïve patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10032-10032.	0.8	1
10	Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example. <i>ESMO Open</i> , 2016, 1, e000021.	2.0	8
11	Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review. <i>Acta Oncologica</i> , 2016, 55, 881-885.	0.8	8
12	Trends in colorectal cancer in the elderly in Denmark, 1980–2012. <i>Acta Oncologica</i> , 2016, 55, 29-39.	0.8	35
13	Efficacy and safety of S-1 and gemcitabine in an unselected Western cohort of patients with unresectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15258-e15258.	0.8	0